Lacouture ME - Search Results

1

Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.

Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. Mitchell EP, et al. Among authors: lacouture me. Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):4-9. Oncology (Williston Park). 2007. PMID: 18154212 Free article. Review.

2

Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.

Lacouture ME. Lacouture ME. Cancer Nurs. 2007 Jul-Aug;30(4 Suppl 1):S17-26. doi: 10.1097/01.NCC.0000281758.85704.9b. Cancer Nurs. 2007. PMID: 17666987 Review.

3

Clinical management of EGFRI dermatologic toxicities: US perspective.

Lacouture ME, Cotliar J, Mitchell EP. Lacouture ME, et al. Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):17-21. Oncology (Williston Park). 2007. PMID: 18154214

4

Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae.

Wagner LI, Lacouture ME. Wagner LI, et al. Among authors: lacouture me. Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):34-6. Oncology (Williston Park). 2007. PMID: 18154217

5

An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.

Eaby B, Culkin A, Lacouture ME. Eaby B, et al. Among authors: lacouture me. Clin J Oncol Nurs. 2008 Apr;12(2):283-90. doi: 10.1188/08.CJON.283-290. Clin J Oncol Nurs. 2008. PMID: 18390464 Review.

6

The growing importance of skin toxicity in EGFR inhibitor therapy.

Lacouture ME. Lacouture ME. Oncology (Williston Park). 2009 Feb;23(2):194, 196. Oncology (Williston Park). 2009. PMID: 19323302 Free article. No abstract available.

7

NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.

Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S. Burtness B, et al. Among authors: lacouture me. J Natl Compr Canc Netw. 2009 May;7 Suppl 1:S5-21; quiz S22-4. doi: 10.6004/jnccn.2009.0074. J Natl Compr Canc Netw. 2009. PMID: 19470276 Review.

8

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Lacouture ME, et al. J Clin Oncol. 2010 Mar 10;28(8):1351-7. doi: 10.1200/JCO.2008.21.7828. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142600 Clinical Trial.

9

Dermatologic toxicities of targeted anticancer therapies.

Balagula Y, Lacouture ME, Cotliar JA. Balagula Y, et al. Among authors: lacouture me. J Support Oncol. 2010 Jul-Aug;8(4):149-61. J Support Oncol. 2010. PMID: 20822032 Review.

10

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.

Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Balagula Y, et al. Among authors: lacouture me. Int J Dermatol. 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791.x. Int J Dermatol. 2011. PMID: 21244375 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

316 results

Search Page